Literature DB >> 18378946

Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis.

Bryan Kestenbaum1, Kyle D Rudser, Ian H de Boer, Carmen A Peralta, Linda F Fried, Michael G Shlipak, Walter Palmas, Catherine Stehman-Breen, David S Siscovick.   

Abstract

BACKGROUND: Kidney disease and hypertension commonly coexist, yet the direction of their association is still debated.
OBJECTIVE: To evaluate whether early kidney dysfunction, measured by serum cystatin C levels and urinary albumin excretion, predates hypertension in adults without clinically recognized kidney or cardiovascular disease.
DESIGN: Observational cohort study using data from 2000 to 2005.
SETTING: The MESA (Multi-Ethnic Study of Atherosclerosis), a community-based study of subclinical cardiovascular disease in adults age 45 to 84 years. PARTICIPANTS: 2767 MESA participants without prevalent hypertension, cardiovascular disease, or clinically recognized kidney disease (an estimated glomerular filtration rate <60 mL/min per 1.73 m2 or microalbuminuria). MEASUREMENTS: Cystatin C was measured by using a nephelometer, and urinary albumin and creatinine were measured from a spot morning collection. The primary outcome was incident hypertension, defined as systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, or use of an antihypertensive medication.
RESULTS: During a median follow-up of 3.1 years, 19.7% of the cohort (545 participants) developed hypertension. After adjustment for established hypertension risk factors, each 15-nmol/L increase in cystatin C was associated with a statistically significant 15% greater incidence of hypertension (P = 0.017). The highest sex-specific quartile of urinary albumin-creatinine ratio was associated with a statistically insignificant 16% greater incidence of hypertension (P = 0.192) compared with the lowest quartile. No statistical evidence suggested a multiplicative interaction. LIMITATIONS: Unmeasured characteristics may have confounded observed associations of kidney markers with hypertension. Follow-up was relatively short. Hypertension that may have occurred between study visits or hypertension that was not captured by standard cuff measurements may have been missed.
CONCLUSION: Differences in kidney function, indicated by cystatin C levels, are associated with incident hypertension among individuals without clinical kidney or cardiovascular disease. These population-based findings complement experimental work implicating early kidney damage in the pathogenesis of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378946      PMCID: PMC3044648          DOI: 10.7326/0003-4819-148-7-200804010-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  37 in total

1.  Hypertension explained by Starling's theory of circulatory homoeostasis.

Authors:  J G BORST; A BORST-DE GEUS
Journal:  Lancet       Date:  1963-03-30       Impact factor: 79.321

2.  Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure?

Authors:  Rachel Huxley; Andrew Neil; Rory Collins
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

3.  Low-grade albuminuria and the risks of hypertension and blood pressure progression.

Authors:  Thomas J Wang; Jane C Evans; James B Meigs; Nader Rifai; Caroline S Fox; Ralph B D'Agostino; Daniel Levy; Ramachandran S Vasan
Journal:  Circulation       Date:  2005-02-28       Impact factor: 29.690

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

Review 5.  'Benign' essential hypertension and kidney damage: a histopathologist's view.

Authors:  A J Howie
Journal:  J Hum Hypertens       Date:  1996-10       Impact factor: 3.012

6.  Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease.

Authors:  Chi-yuan Hsu; Charles E McCulloch; Jeanne Darbinian; Alan S Go; Carlos Iribarren
Journal:  Arch Intern Med       Date:  2005-04-25

7.  Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group.

Authors:  V M Buckalew; R L Berg; S R Wang; J G Porush; S Rauch; G Schulman
Journal:  Am J Kidney Dis       Date:  1996-12       Impact factor: 8.860

8.  Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension.

Authors:  T F Andoh; R J Johnson; T Lam; W M Bennett
Journal:  Am J Transplant       Date:  2001-09       Impact factor: 8.086

9.  Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System.

Authors:  E J Erlandsen; E Randers; J H Kristensen
Journal:  Scand J Clin Lab Invest       Date:  1999-02       Impact factor: 1.713

10.  Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy.

Authors:  T Zelmanovitz; J L Gross; J Oliveira; M J de Azevedo
Journal:  Diabetes Care       Date:  1998-07       Impact factor: 19.112

View more
  48 in total

1.  Association of kidney function and albuminuria with prevalent and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Minxuan Huang; Kunihiro Matsushita; Yingying Sang; Shoshana H Ballew; Brad C Astor; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2014-08-21       Impact factor: 8.860

2.  Association of left ventricular hypertrophy with incident hypertension: the multi-ethnic study of atherosclerosis.

Authors:  Daichi Shimbo; Paul Muntner; Devin Mann; R Graham Barr; Weihong Tang; Wendy Post; Joao Lima; Gregory Burke; David Bluemke; Steven Shea
Journal:  Am J Epidemiol       Date:  2011-03-21       Impact factor: 4.897

Review 3.  Target organ damage in African American hypertension: role of APOL1.

Authors:  Barry I Freedman; Mariana Murea
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

4.  Relationship between serum cystatin C and hypertension among US adults without clinically recognized chronic kidney disease.

Authors:  Anoop Shankar; Srinivas Teppala
Journal:  J Am Soc Hypertens       Date:  2011-04-17

Review 5.  Association of cystatin C with adverse outcomes.

Authors:  Magdalena Madero; Mark J Sarnak
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-05       Impact factor: 2.894

6.  Genetic basis of nondiabetic end-stage renal disease.

Authors:  Barry I Freedman; Rulan S Parekh; W H Linda Kao
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

7.  Elevated serum cystatin C in severe OSA younger men without complications.

Authors:  Xiao-Bin Zhang; Qi-Chang Lin; Chao-Sheng Deng; Gong-Ping Chen; Zhi-Ming Cai; Hua Chen
Journal:  Sleep Breath       Date:  2012-03-16       Impact factor: 2.816

8.  Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Paul Muntner; Mark Woodward; Devin M Mann; Daichi Shimbo; Erin D Michos; Roger S Blumenthal; April P Carson; Haiying Chen; Donna K Arnett
Journal:  Hypertension       Date:  2010-05-03       Impact factor: 10.190

9.  Structural and functional vascular alterations and incident hypertension in normotensive adults: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Carmen A Peralta; Kathryn L Adeney; Michael G Shlipak; David Jacobs; Daniel Duprez; David Bluemke; Joseph Polak; Bruce Psaty; Bryan R Kestenbaum
Journal:  Am J Epidemiol       Date:  2009-11-30       Impact factor: 4.897

10.  High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo.

Authors:  Ernest K Sumaili; Eric P Cohen; Chantal V Zinga; Jean-Marie Krzesinski; Nestor M Pakasa; Nazaire M Nseka
Journal:  BMC Nephrol       Date:  2009-07-21       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.